Atea Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel oral antivirals for serious viral diseases. The company's lead program combines bemnifosbuvir and ruzasvir as a protease inhibitor-free treatment for hepatitis C virus with advantages including pan-genotypic potency, an eight-week regimen duration, and a favorable drug-interaction profile; it has also entered clinical development with AT-587, a first-in-class direct-acting antiviral for hepatitis E virus in immunocompromised patients. Atea relies on a proprietary nucleoside and nucleotide platform developed over decades, retains global rights to its candidates through a partnership with Merck, and plans to generate revenue through milestone payments from partners and royalties on net sales from commercial collaborators who will manufacture and distribute the products.